Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Pilot Study of Intralesional Immunotherapy With A Recombinant Avipox Virus Engineered To Express A Triad Of Co-Stimulatory Molecules In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck

NCT00021424 is registered in ClinicalTrials.gov with National Institute on Deafness and Other Communication Disorders (NIDCD) as lead sponsor.

NCT NCT00021424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00021424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Pilot Study of Intralesional Immunotherapy With A Recombinant Avipox Virus Engineered To Express A Triad Of Co-Stimulatory Molecules In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2001
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, metastatic cancer